30 Aug 2019 07:00
30 August 2019
Amryt Pharma plc
("Amryt" or the "Company")
Director and PDMR share purchases
Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that, following the announcement on 27 August 2019 with respect to, inter alia, an Interim Placing to raise $8.0 million, the 4,580,288 Initial Interim Placing Shares have been admitted to trading on AIM today. Ray Stafford, a Non-Executive Director of the Company, subscribed for 918,273 Initial Interim Placing Shares pursuant to the Interim Placing. Following this subscription, Ray Stafford has an interest in 1,301,001 ordinary shares representing approximately 2.6 per cent. of the enlarged issued share capital of the Company.
The total issued ordinary share capital of the Company following admission of the Initial Interim Placing Shares is 50,383,169 ordinary shares.
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Ray Stafford | |||
2. | Reason for the notification | ||||
a) | Position / status | Non-Executive Director | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.06 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 27 August 2019 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.90 | 918,273 | ||||
e) | Aggregated information ·; Aggregated volume ·; Aggregated price |
918,273 £826,445.70 | |||
f) | Date of the transaction | 30 August 2019 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
Enquiries:
Amryt Pharma plc | +353 (1) 518 0200 |
Dr. Joe Wiley, CEO Rory Nealon, CFO/COO | |
Shore Capital | +44 (0) 20 7408 4090 |
Financial Adviser, Nominated Adviser and Joint Broker | |
Edward Mansfield, Mark Percy, Daniel Bush, John More
| |
Stifel | +44 (0) 20 7710 7600 |
Joint Broker | |
Jonathan Senior, Ben Maddison | |
Davy | +353 (1) 679 6363 |
Euronext Growth Advisor and Joint Broker | |
John Frain, Daragh O'Reilly | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Amber Fennell, Matthew Neal, David Daley |
All defined terms used in this announcement not otherwise defined have the meanings set out in the Admission Document dated 27 August 2019.